Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor γ

Prostaglandins and Other Lipid Mediators

Volumn 93, Issue 3-4, 2010, Pages 126-133

  Tsukahara, Tamotsu ^a   Hanazawa, Shuwa ^b   Kobayashi, Tetsuyuki ^b   Iwamoto, Yoshiki ^a   Murakami Murofushi, Kimiko ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OCHANOMIZU UNIVERSITY   (Japan)

Author keywords

Colon cancer; Lysophospholipid; Nuclear receptor; Peroxisome proliferator activated receptor gamma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDIC ACID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HT29; CELL SURVIVAL; CELL TYPE; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DNA; HETEROCYCLIC COMPOUNDS, 1-RING; HT29 CELLS; HUMANS; LYSOPHOSPHOLIPIDS; PHOSPHATIDIC ACIDS; PPAR GAMMA;

EID: 78149416565     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.09.002     Document Type: Article

References (48)

1. ACS Cancer Facts and Figures 2008, American Cancer Society, Atlanta.
2. Hegde S.R., Sun W., Lynch J.P. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2008, 2(1):135-149.
3. Evans R.M. The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 2005, 19(6):1429-1438.
4. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998, 1(3):465-470.
5. Elstner E., Muller C., Koshizuka K., et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95(15):8806-8811.
6. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007, 1771(8):926-935.
7. Puigserver P., Adelmant G., Wu Z., et al. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999, 286(5443):1368-1371.
8. Ge K., Guermah M., Yuan C.X., et al. Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature 2002, 417(6888):563-567.
9. Yu C., Markan K., Temple K.A., Deplewski D., Brady M.J., Cohen R.N. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem 2005, 280(14):13600-13605.
10. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83(5):803-812.
11. McIntyre T.M., Pontsler A.V., Silva A.R., et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003, 100(1):131-136.
12. Tsukahara T., Tsukahara R., Yasuda S., et al. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J Biol Chem 2006, 281(6):3398-3407.
13. Davies S.S., Pontsler A.V., Marathe G.K., et al. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 2001, 276(19):16015-16023.
14. Schopfer F.J., Lin Y., Baker P.R., et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 2005, 102(7):2340-2345.
15. Elte J.W., Blickle J.F. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007, 18(1):18-25.
16. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 2009, 15(1):2-8.
17. Schaefer K.L., Wada K., Takahashi H., et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005, 65(6):2251-2259.
18. Tsukahara T., Tsukahara R., Fujiwara Y., et al. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARγ by cyclic phosphatidic acid. Mol Cell 2010, 39:421-432.
19. Fujiwara Y. Cyclic phosphatidic acid-a unique bioactive phospholipid. Biochim Biophys Acta 2008, 1781(9):519-524.
20. Friedman P., Haimovitz R., Markman O., Roberts M.F., Shinitzky M. Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D. J Biol Chem 1996, 271(2):953-957.
21. Kobayashi T., Tanaka-Ishii R., Taguchi R., Ikezawa H., Murakami-Murofushi K. Existence of a bioactive lipid, cyclic phosphatidic acid, bound to human serum albumin. Life Sci 1999, 65(21):2185-2191.
22. Murakami-Murofushi K., Uchiyama A., Fujiwara Y., et al. Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochim Biophys Acta 2002, 1582(1-3):1-7.
23. Mukai M., Imamura F., Ayaki M., et al. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). Int J Cancer 1999, 81(6):918-922.
24. Martinasso G., Oraldi M., Trombetta A., et al. Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Res 2007, 2007:93416.
25. Zhang Y.Q., Tang X.Q., Sun L., et al. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 2007, 13(10):1534-1540.
26. Choi I.K., Kim Y.H., Kim J.S., Seo J.H. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Invest New Drugs 2008, 26(3):283-288.
27. Schaefer K.L., Takahashi H., Morales V.M., et al. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int J Cancer 2007, 120(3):702-713.
28. Girnun G.D., Smith W.M., Drori S., et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002, 99(21):13771-13776.
29. Yang K., Fan K.H., Lamprecht S.A., et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int J Cancer 2005, 116(4):495-499.
30. Liu D., el-Hariry I., Karayiannakis A.J., et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997, 77(6):557-563.
31. Rodrigues N.R., Rowan A., Smith M.E., et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990, 87(19):7555-7559.
32. Narayan S., Jaiswal A.S. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. J Biol Chem 1997, 272(49):30619-30622.
33. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290(5493):989-992.
34. Chiu S.J., Hsaio C.H., Tseng H.H., et al. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun 2010, 394(3):774-779.
35. Lowry R.R., Tinsley I.J. A simple, sensitive method for lipid phosphorus. Lipids 1974, 9(7):491-492.
36. Uchiyama A., Mukai M., Fujiwara Y., et al. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta 2007, 1771(1):103-112.
37. Kobayashi S., Tokunoh R., Shibasaki M., Shinagawa M., Murakami-Murofushi K. Synthesis of 1-O-acylgrycelol 2,3-cyclic phosphate: determination of the absolute structure of PHYLPA. A specific inhibitor of DNA polymerase α. Tetrahedron Lett 1993, 34:4047-4050.
38. Baker D.L., Desiderio D.M., Miller D.D., Tolley B., Tigyi G.J. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 2001, 292(2):287-295.
39. Gupta R.A., Brockman J.A., Sarraf P., Willson T.M., DuBois R.N. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 2001, 276(32):29681-29687.
40. Baker D.L., Fujiwara Y., Pigg K.R., et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 2006, 281(32):22786-22793.
41. Prestwich G.D., Gajewiak J., Zhang H., Xu X., Yang G., Serban M. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 2008, 1781(9):588-594.
42. Shida D., Kitayama J., Yamaguchi H., et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 2003, 63(7):1706-1711.
43. Lee M., Choi S., Hallden G., Yo S.J., Schichnes D., Aponte G.W. P2Y5 is a G{alpha}i, G{alpha}12/13 G protein coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. Am J Physiol Gastrointest Liver Physiol 2009.
44. Seargent J.M., Yates E.A., Gill J.H. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 2004, 143(8):933-937.
45. Fehlberg S., Trautwein S., Goke A., Goke R. Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners. Biochem J 2002, 362(Pt 3):573-578.
46. Lee G., Elwood F., McNally J., et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2002, 277(22):19649-19657.
47. Hisatake J.I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H.P. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000, 60(19):5494-5498.
48. Voutsadakis I.A. Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J Cancer Res Clin Oncol 2007, 133(12):917-928.